Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Testing a Claim about Standard Deviation01:19

Testing a Claim about Standard Deviation

2.5K
A complete procedure to test a claim about population standard deviation or population variance is explained here.
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
2.5K
The Anchoring-and-Adjustment Heuristic01:25

The Anchoring-and-Adjustment Heuristic

7.3K
In order to make good decisions, we use our knowledge and our reasoning. Often, this knowledge and reasoning is sound and solid. However, sometimes, we are swayed by biases or by others manipulating a situation. For example, let’s say you and three friends wanted to rent a house and had a combined target budget of $1,600. The realtor shows you only very run-down houses for $1,600 and then shows you a very nice house for $2,000. Might you ask each person to pay more in rent to get the...
7.3K
Ratio Level of Measurement00:54

Ratio Level of Measurement

18.4K
The way a set of data is measured is called its level of measurement. Correct statistical procedures depend on a researcher being familiar with levels of measurement. For analysis, data are classified into four levels of measurement—nominal, ordinal, interval, and ratio.
A set of data measured using the ratio scale takes care of the ratio problem and provides complete information. Ratio scale data are like interval scale data, except they have a zero point and ratios can be calculated....
18.4K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Difference from Background: Limit of Detection01:05

Difference from Background: Limit of Detection

6.7K
The limit of detection (LOD) is the smallest amount of analyte that can be distinguished from the background noise. The LOD value corresponds to the concentration at which the analyte signal is three times larger than the standard deviation of the blank signal. Below this value, the analyte signal cannot be differentiated from the background noise. It is calculated by dividing the calibration slope by 3 times the standard deviation of the blank signals.
The LOD indicates the presence or absence...
6.7K
Drug Nomenclature01:17

Drug Nomenclature

1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[DNA informs on ancient partner choice].

Medecine sciences : M/S·2026
Same author

[TimeVaults provide recordings of past cellular activity].

Medecine sciences : M/S·2026
Same author

[In vivo CAR-Ts, a significant breakthrough].

Medecine sciences : M/S·2026
Same author

[House of cards?]

Medecine sciences : M/S·2026
Same author

[Towards gene therapy for Hutington's disease].

Medecine sciences : M/S·2025
Same author

[DNA reveals the living world].

Medecine sciences : M/S·2025

Related Experiment Video

Updated: Jul 25, 2025

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance
03:54

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance

Published on: October 19, 2018

6.2K

[New, more expensive - Not necessarily better].

Bertrand Jordan1

  • 1Biologiste, généticien et immunologiste, président d'Aprogène (association pour la promotion de la génomique), 13007 Marseille, France.

Medecine Sciences : M/S
|June 30, 2023
PubMed
Summary
This summary is machine-generated.

New cancer drug prices often exceed $100,000 without proven efficacy. Effective regulation is needed to control these high oncology drug costs and ensure fair market competition.

More Related Videos

Advanced Workflow for Taking High-Quality Increment Cores - New Techniques and Devices
07:40

Advanced Workflow for Taking High-Quality Increment Cores - New Techniques and Devices

Published on: March 10, 2023

2.2K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

459

Related Experiment Videos

Last Updated: Jul 25, 2025

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance
03:54

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance

Published on: October 19, 2018

6.2K
Advanced Workflow for Taking High-Quality Increment Cores - New Techniques and Devices
07:40

Advanced Workflow for Taking High-Quality Increment Cores - New Techniques and Devices

Published on: March 10, 2023

2.2K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

459

Area of Science:

  • Health Economics
  • Oncology Drug Pricing
  • Pharmaceutical Policy

Context:

  • High costs of new oncology drugs are a significant concern.
  • Pricing often exceeds $100,000 USD.
  • Lack of correlation between price and improved clinical efficacy.

Purpose:

  • To analyze the pricing strategies of new oncology drugs.
  • To examine the relationship between drug cost and clinical benefit.
  • To advocate for regulatory intervention in drug pricing.

Summary:

  • New oncology drugs frequently cost over $100,000.
  • This high cost does not consistently reflect superior clinical efficacy.
  • Companies utilize a 'what the market can bear' pricing model.

Impact:

  • Highlights the need for regulatory oversight in the pharmaceutical market.
  • Suggests potential for cost containment in cancer care.
  • Emphasizes the importance of value-based pricing for new therapies.